Profund Advisors LLC Has $2.12 Million Holdings in Scholar Rock Holding Corporation $SRRK

Profund Advisors LLC grew its stake in Scholar Rock Holding Corporation (NASDAQ:SRRK) by 57.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 48,152 shares of the company’s stock after buying an additional 17,501 shares during the quarter. Profund Advisors LLC’s holdings in Scholar Rock were worth $2,121,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. JPMorgan Chase & Co. boosted its holdings in shares of Scholar Rock by 161.0% in the third quarter. JPMorgan Chase & Co. now owns 713,988 shares of the company’s stock valued at $26,589,000 after buying an additional 440,401 shares during the period. HighVista Strategies LLC boosted its holdings in Scholar Rock by 90.8% during the third quarter. HighVista Strategies LLC now owns 59,573 shares of the company’s stock worth $2,218,000 after purchasing an additional 28,343 shares during the last quarter. Nan Fung Trinity HK Ltd. acquired a new position in Scholar Rock during the third quarter worth $1,402,000. Eagle Health Investments LP boosted its holdings in Scholar Rock by 34.9% during the third quarter. Eagle Health Investments LP now owns 363,300 shares of the company’s stock worth $13,529,000 after purchasing an additional 93,900 shares during the last quarter. Finally, Jennison Associates LLC boosted its holdings in Scholar Rock by 74.0% during the fourth quarter. Jennison Associates LLC now owns 2,795,188 shares of the company’s stock worth $123,128,000 after purchasing an additional 1,188,676 shares during the last quarter. Institutional investors and hedge funds own 91.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on SRRK. Truist Financial increased their target price on shares of Scholar Rock from $44.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. Piper Sandler increased their target price on shares of Scholar Rock from $51.00 to $58.00 and gave the stock an “overweight” rating in a report on Wednesday, March 4th. Canaccord Genuity Group began coverage on shares of Scholar Rock in a report on Monday, April 20th. They set a “buy” rating and a $62.00 target price for the company. BMO Capital Markets increased their target price on shares of Scholar Rock from $50.00 to $70.00 and gave the stock an “outperform” rating in a report on Wednesday, March 4th. Finally, Raymond James Financial restated a “strong-buy” rating on shares of Scholar Rock in a report on Tuesday, March 3rd. Five equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $56.00.

Insider Activity

In other Scholar Rock news, COO Keith Woods sold 10,220 shares of the company’s stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $49.57, for a total transaction of $506,605.40. Following the sale, the chief operating officer directly owned 620,055 shares of the company’s stock, valued at approximately $30,736,126.35. This represents a 1.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Vikas Sinha sold 10,410 shares of the company’s stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $49.57, for a total transaction of $516,023.70. Following the sale, the chief financial officer directly owned 619,856 shares in the company, valued at $30,726,261.92. This trade represents a 1.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 71,975 shares of company stock valued at $3,546,591. 13.30% of the stock is owned by corporate insiders.

Scholar Rock Stock Performance

NASDAQ SRRK opened at $47.56 on Wednesday. The company has a current ratio of 8.64, a quick ratio of 8.64 and a debt-to-equity ratio of 0.71. The firm’s fifty day moving average price is $46.73 and its two-hundred day moving average price is $44.12. Scholar Rock Holding Corporation has a 1 year low of $27.07 and a 1 year high of $51.63. The firm has a market capitalization of $5.70 billion, a P/E ratio of -13.25 and a beta of 0.70.

Scholar Rock (NASDAQ:SRRK) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.01). During the same period in the previous year, the company earned ($0.67) EPS. As a group, research analysts anticipate that Scholar Rock Holding Corporation will post -3.18 EPS for the current year.

Scholar Rock Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).